about
Hereditary Cancer: Example of a Public Health Approach to Ensure Population Health Benefits of Genetic MedicinePancreatic Cancer from Molecular Pathways to Treatment OpinionPancreatic cancer from bench to bedside: molecular pathways and treatment optionsRole of Biomarkers in the Development of PARP InhibitorsState of the art biological therapies in pancreatic cancerBreast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic PhenotypeNot All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation DetectionUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineSynergistic effects of a novel lipid-soluble extract from Pinellia pedatisecta Schott and cisplatin on human cervical carcinoma cell lines through the regulation of DNA damage response signaling pathway"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsDNA repair mechanisms in cancer development and therapyPARPs and ADP-Ribosylation: 50 Years … and Counting.BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach.Poly(ADP-ribose) polymerase 1 is a novel target to promote axonal regeneration.[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancerThe impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safetyResponse of BRCA1-mutated gallbladder cancer to olaparib: A case report.Millepachine, a potential topoisomerase II inhibitor induces apoptosis via activation of NF-κB pathway in ovarian cancer.Reverse the Resistance to PARP Inhibitors.Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer.Veliparib for the treatment of ovarian cancer.A Study on the Anticarcinogenic Effects of Calcium Fructoborate.Generation of small molecules to interfere with regulated necrosis.Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.Evaluation of aromatic radiobromination by nucleophilic substitution using diaryliodonium salt precursors.Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer.Miltirone-induced apoptosis in cisplatin-resistant lung cancer cells through upregulation of p53 signaling pathways.Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case reportPoly(ADP-ribose) polymerase 1 searches DNA via a 'monkey bar' mechanism
P2860
Q26740273-3EC03DAD-03DD-4A51-9914-C2C5403B1C7DQ26743482-37DAD2BF-29E1-422C-8D0D-CFCF6A3296BDQ26747524-3CDBC61E-6560-48A8-A7D7-60FEA5B9BCECQ26753159-954812DA-C317-431E-AAFA-F2D9AC23D56DQ26769941-6895E122-5267-473E-AA3F-D1BD48336723Q26776113-6B0387C0-7F0E-4CD9-852D-A4AD36F17D32Q26801745-93F393CB-AE30-403A-91D3-88411DEA7D44Q28071541-492FC5AA-1C10-4C59-A142-7DC89A359ECDQ28072204-17E3545C-D4CB-436B-9023-BD4161812C60Q33597926-D22748EB-752A-49D7-AC28-B3846C6F6D45Q33618910-24E22414-14DD-4C35-AA4C-2F706E934F49Q35531287-AFB30929-8FB9-4C90-AB90-5FF955C50B30Q35769075-E06B4324-D041-42AA-966C-C4DB995D2257Q35909731-78EA774F-1723-478B-8704-B945CB5580DFQ36257738-37A57793-86BF-46D2-AFA4-9AA1A0FCFBEAQ36259861-B467AA84-403B-4273-87AE-F7EC931EFA8FQ36371538-E51F0091-095C-4F2E-A8A9-EEC7CF877DACQ36568348-0DAEBC1F-E80A-43C1-B5A4-3011FEC54D46Q36717832-228FE14A-3C6D-41C9-9AA9-89C07AAAF857Q37501085-AE6DF7E7-0166-485B-94AF-8E33705FBEB3Q37588443-D10092B4-4801-4885-9D9E-E81CB00E1AA4Q37675896-2E428AD4-B1D7-4949-9CB7-B646B2425013Q38596368-66B4824F-98E5-41D8-B246-15B0623F2A14Q38682031-FA2FCDDD-EF02-4E3D-BB3F-E1EDCD120A90Q38710466-BA34D513-CD8C-43E3-AD8F-29F95C519141Q38724030-B3826343-393C-4592-8DE4-177BC7E47B77Q38799144-91FBC5C6-F6ED-4FC8-8C71-901E327526F5Q39004424-CBBD0E1B-7008-49C2-BDF8-D3254F7AC3CEQ41133627-9DE52CEB-1F75-4BFA-97DE-859CDC5AA6FDQ45790068-21DE843B-40A7-4999-96B3-A67DA7B73E39Q47953839-EF023FE9-E044-461F-A85F-326935982F24Q48110323-9E071D31-9DE3-4C6C-8485-5310BC266ABFQ48133925-69422755-EC47-46F7-A812-FA2FE042203DQ49852384-24AB4FB5-8C43-4944-A203-8A816D588ECFQ55347991-5A8D9CDF-8262-4142-9A28-DB4E9F97B097Q58605214-9519E282-D643-440C-9ED5-07A65E4C66ECQ58794907-50AE7C96-5FE3-4CEB-BB73-7D35EA81BE6E
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
PARP inhibitors: A new era of targeted therapy.
@en
type
label
PARP inhibitors: A new era of targeted therapy.
@en
prefLabel
PARP inhibitors: A new era of targeted therapy.
@en
P2093
P1433
P1476
PARP inhibitors: A new era of targeted therapy.
@en
P2093
Paige Baldwin
Shifalika Tangutoori
Srinivas Sridhar
P356
10.1016/J.MATURITAS.2015.01.015
P577
2015-02-07T00:00:00Z